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Background
Respiratory syncytial virus (RSV) is known to cause
bronchiolitis and other upper respiratory infections (URIs) in
children <1 year old predictably around fall and winter
seasons. However, given the COVID-19 pandemic and the
resultant lockdowns, circulation of other respiratory viruses
was uncharacteristically low. Restrictions are quickly falling
and with increased interaction there has been an
uncharacteristic jump in cases.

Purpose
To summarize the pathogenesis of RSV and the
mechanisms the virus uses to evade immune responses.
Additional discussion of the increased rates of RSV
hospitalizations as well as the role of vaccinations in
controlling infection.

Increased RSV Hospitalizations
According to CDC preliminary data, RSV hospitalizations for the 2022-2023 year
starting in October have already more than doubled case numbers from previous years.
As per Figure 1, October and November 2022 reported cases at 11.8 and 19.0 per
100,000 people, respectively, across all ages compared to a 4.2 and 4.8 in October and
November 2021. As seen in 2018-2019 and 2019-2020 most cases occurred in the fall
and winter (October-February), a stark contrast to the nearly nil cases in those same
months of 2020-2021. The strictest social distancing restrictions were uplifted by
summer 2021, and consequently the rates in 2021-2022 show the highest rate of
hospitalizations among the summer months. These then reach the overall peak in
November 2022. As seen in Figure 2, the number of hospitalizations in children <4
years, 64.2 per 100,000, was 6x higher any other age range.

Fig. 1. Number of
RSV-associated
hospitalizations in
the US by month,
per 100,000

Pathogenesis
RSV largely affects children less than 2 years old, with the
majority being <1-year-old. The virus infects respiratory
ciliated epithelia, starting with the nasal passages, that then
secrete proinflammatory cytokines and recruit an array of
immune cells. Lower down the respiratory pathway, the
virus also infects type II alveolar cells. The naivete of the
immune systems of <1 year-old children helps illuminate
how this virus disparately affects this demographic.

G protein is a transmembrane protein that governs
much of the infectivity through various methods,
including assisting virus attachment to cells, binding
to cytokines that then induce innate immune cells,
disrupting antibody recognition due to its heavy
glycosylation, and creating truncated G proteins that
act as decoys for antibodies.
F protein is another transmembrane protein that
works with G protein to facilitate fusion of the viral
particle to respiratory cells. The G and F proteins are
by far the largest proteins of RSV, displaying 230 and
270 epitopes, respectively, with the next largest
protein having 100 epitopes and the rest with less
than 50.
NS2 protein (non-structural 2 protein) which induces
shedding of the infected respiratory cells, clearing
some infection, but in turn results in obstructed
airways.

Role of Vaccinations
As recent as 2014, the development of a vaccine
against RSV was elusive due to the difficulty in
balancing
immunogenicity
and
attenuation.
Palivizumab, an antibody against RSV, has been
used since its approval in 1998 to prevent infection
only in high-risk babies. Current vaccine
development is underway with the goal of providing
all children with immunity to developing disease, not
just controlling severity. Given their vital roles in
achieving infection, F and G proteins will likely have a
part to play in an effective vaccine.

Method
A literature review on PubMed was done including
keywords
“RSV”
“COVID”
“immunogenicity”
“pathogenesis”. Retrospective cohort studies and
overviews of infectivity were included in discussion. CDC
data regarding RSV hospitalizations was also used.

Pathogenesis (cont.)

Fig. 2. Number of
RSV-associated
hospitalizations in
the US by age,
per 100,000
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